Treatment of anicteric acute hepatitis C with peginterferon alpha-2a plus ribavirin
Background. Hepatitis C virus (HCV) infection is the most frequent cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma in the world. Acute hepatitis C is the most commonly asymptomatic liver disease with the development of chronic HCV infection in the majority of infected patients. S...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ministry of Defence of the Republic of Serbia, University of Defence, Belgrade
2005-01-01
|
| Series: | Vojnosanitetski Pregled |
| Subjects: | |
| Online Access: | http://www.doiserbia.nb.rs/img/doi/0042-8450/2005/0042-84500511865D.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849414594736422912 |
|---|---|
| author | Delić Dragan Nešić Zorica I. Prostran Milica Š. Simonović Jasmina Švirtlih Neda |
| author_facet | Delić Dragan Nešić Zorica I. Prostran Milica Š. Simonović Jasmina Švirtlih Neda |
| author_sort | Delić Dragan |
| collection | DOAJ |
| description | Background. Hepatitis C virus (HCV) infection is the most frequent cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma in the world. Acute hepatitis C is the most commonly asymptomatic liver disease with the development of chronic HCV infection in the majority of infected patients. Studies of the natural history of HCV infection suggest that only 15-30% of patients with acute infection recover spontaneously. Others, up to 85% of the infected patients develop chronic hepatitis C. Acute hepatitis C is so uncommon and with the unpredictable occurrence, and of the low frequency, that it is difficult to determine the optimal treatment of this disease. There have been many randomized, controlled trials of the therapy in patients with chronic hepatitis C, but none of an adequate size or rigor in patients with acute hepatitis C. Therefore, the causal treatment of patients with acute hepatitis C aimed at the prevention of chronic liver disease is necessary. Case report. We have treated a patient with anicteric form of acute hepatitis C after a three-month outpatient follow-up using a combined therapy: pegylated interferon-alpha 2a, 180 μg, subcutaneously, once a week plus ribavirin 1000 mg orally once a day. The treatment lasted 24 weeks. Stable biochemical and virological response was achieved both at the end of the treatment and 6 months after the completion of the therapy. Conclusion. We believe that the above mentioned might be one of the approaches to the treatment of acute hepatitis C. However, further prospective studies with significantly larges number of patients are necessary for the definite conclusions about the treatment of HCV infections. |
| format | Article |
| id | doaj-art-72ceaf888bcb43338a10e84b0dbc58b1 |
| institution | Kabale University |
| issn | 0042-8450 |
| language | English |
| publishDate | 2005-01-01 |
| publisher | Ministry of Defence of the Republic of Serbia, University of Defence, Belgrade |
| record_format | Article |
| series | Vojnosanitetski Pregled |
| spelling | doaj-art-72ceaf888bcb43338a10e84b0dbc58b12025-08-20T03:33:46ZengMinistry of Defence of the Republic of Serbia, University of Defence, BelgradeVojnosanitetski Pregled0042-84502005-01-01621186586810.2298/VSP0511865DTreatment of anicteric acute hepatitis C with peginterferon alpha-2a plus ribavirinDelić DraganNešić Zorica I.Prostran Milica Š.Simonović JasminaŠvirtlih NedaBackground. Hepatitis C virus (HCV) infection is the most frequent cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma in the world. Acute hepatitis C is the most commonly asymptomatic liver disease with the development of chronic HCV infection in the majority of infected patients. Studies of the natural history of HCV infection suggest that only 15-30% of patients with acute infection recover spontaneously. Others, up to 85% of the infected patients develop chronic hepatitis C. Acute hepatitis C is so uncommon and with the unpredictable occurrence, and of the low frequency, that it is difficult to determine the optimal treatment of this disease. There have been many randomized, controlled trials of the therapy in patients with chronic hepatitis C, but none of an adequate size or rigor in patients with acute hepatitis C. Therefore, the causal treatment of patients with acute hepatitis C aimed at the prevention of chronic liver disease is necessary. Case report. We have treated a patient with anicteric form of acute hepatitis C after a three-month outpatient follow-up using a combined therapy: pegylated interferon-alpha 2a, 180 μg, subcutaneously, once a week plus ribavirin 1000 mg orally once a day. The treatment lasted 24 weeks. Stable biochemical and virological response was achieved both at the end of the treatment and 6 months after the completion of the therapy. Conclusion. We believe that the above mentioned might be one of the approaches to the treatment of acute hepatitis C. However, further prospective studies with significantly larges number of patients are necessary for the definite conclusions about the treatment of HCV infections.http://www.doiserbia.nb.rs/img/doi/0042-8450/2005/0042-84500511865D.pdfhepatitis Cchronichepacivirusinterferon-alpharibavirin |
| spellingShingle | Delić Dragan Nešić Zorica I. Prostran Milica Š. Simonović Jasmina Švirtlih Neda Treatment of anicteric acute hepatitis C with peginterferon alpha-2a plus ribavirin Vojnosanitetski Pregled hepatitis C chronic hepacivirus interferon-alpha ribavirin |
| title | Treatment of anicteric acute hepatitis C with peginterferon alpha-2a plus ribavirin |
| title_full | Treatment of anicteric acute hepatitis C with peginterferon alpha-2a plus ribavirin |
| title_fullStr | Treatment of anicteric acute hepatitis C with peginterferon alpha-2a plus ribavirin |
| title_full_unstemmed | Treatment of anicteric acute hepatitis C with peginterferon alpha-2a plus ribavirin |
| title_short | Treatment of anicteric acute hepatitis C with peginterferon alpha-2a plus ribavirin |
| title_sort | treatment of anicteric acute hepatitis c with peginterferon alpha 2a plus ribavirin |
| topic | hepatitis C chronic hepacivirus interferon-alpha ribavirin |
| url | http://www.doiserbia.nb.rs/img/doi/0042-8450/2005/0042-84500511865D.pdf |
| work_keys_str_mv | AT delicdragan treatmentofanictericacutehepatitiscwithpeginterferonalpha2aplusribavirin AT nesiczoricai treatmentofanictericacutehepatitiscwithpeginterferonalpha2aplusribavirin AT prostranmilicas treatmentofanictericacutehepatitiscwithpeginterferonalpha2aplusribavirin AT simonovicjasmina treatmentofanictericacutehepatitiscwithpeginterferonalpha2aplusribavirin AT svirtlihneda treatmentofanictericacutehepatitiscwithpeginterferonalpha2aplusribavirin |